UBS keeps A$26.00 target for Telix Pharmaceuticals stock

Published on 10/15/2026 at 20:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Telix posted A$679.47 million revenue for the quarter ending June 30, 2026. Telix Pharmaceuticals stock costs EUR 9.42 on October 15, 2026.

Analyst target and business figures

UBS maintained its Buy rating and A$26.00 target on October 11, 2026.
Quarterly revenue reached A$679.47 million for the period ending June 30, 2026.
Telix Pharmaceuticals stock costs EUR 9.42 at Lang & Schwarz on October 15, 2026 at 8:32 p.m. CEST, while the ASX session was down 1.69 percent.
Telix had an AUD 5.1 billion market capitalization as of October 15, 2026.

Telix, AU000000TLX2, Illustration mit AI erstellt.

UBS maintained a Buy rating and an A$26.00 price target for Telix Pharmaceuticals in a report dated October 11, 2026, according to Markets Insider. Against the ASX price of AUD 15.08 on October 15, 2026, the target stands 72.41 percent higher in the same currency. Telix Pharmaceuticals stock was at EUR 9.42 at Lang & Schwarz on October 15, 2026 at 8:32 p.m. CEST.

Revenue provides the operating anchor

The same Markets Insider report cited quarterly revenue of A$679.47 million for the period ending June 30, 2026, compared with A$593.11 million in the comparable prior-year period. It also reported net profit of A$54.56 million, versus a GAAP net loss of A$3.48 million a year earlier.

Price position and valuation

Telix closed its ASX session at AUD 15.08 on October 15, 2026 at 4:14 p.m. AEDT, down 1.69 percent from AUD 15.34. The company had a market capitalization of AUD 5.1 billion, a trailing P/E ratio of 117.63 and no indicated dividend yield as of the same date. The UBS target of A$26.00 therefore remains materially above the latest ASX quotation, while the euro quote reflects the German trading perspective.

Comparison with peers

Telix: minus 1.69 percent, P/E 117.63, market capitalization AUD 5.1 billion
CSL (ASX, AUD): plus 1.25 percent, P/E minus 24.40, market capitalization AUD 89.7 billion
ResMed (ASX, AUD): plus 0.03 percent, P/E 23.20, market capitalization AUD 47.3 billion.

Next dates and recent products

Telix's investor calendar lists its H1 2026 results webcast on August 19, 2026 and its R&D Day on September 22, 2026. The company's investor page also identifies Telix as a radiopharmaceutical developer focused on diagnostic and therapeutic products. On October 6, 2026, Telix announced that the first patients had been dosed with its FDA-approved brain cancer imaging drug Pixclara, a dated product milestone that sits behind the current market view.

What the target means for the stock

The key contrast is between the current valuation and the analyst target. UBS's A$26.00 target is 72.41 percent above the ASX price of AUD 15.08, while the business figure cited for the June 30, 2026 quarter showed revenue of A$679.47 million and net profit of A$54.56 million.

German trading view

The euro quote stood at EUR 9.42 at Lang & Schwarz on October 15, 2026 at 8:32 p.m. CEST. The ASX session had closed at AUD 15.08 on October 15, 2026, down 1.69 percent from AUD 15.34.